Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.38 |
| ▸ | PPARG | P37231 | 7/20 | 0.38 |
| ▸ | PPARD | Q03181 | 7/20 | 0.38 |
| ▸ | PPARA | Q07869 | 7/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 2/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.38 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2704033 | 1.00 | AKR1B1 (0.39) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL10521386 | 1.00 | AKR1B1 (0.39) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL5038748 | 0.89 | CA1 (0.35) | TSHRMEN1KMT2A | |
| SCHEMBL14367747 | 0.85 | PAOX (0.38) | ALDH1A1 | |
| SCHEMBL24611764 | 0.85 | AKR1B1 (0.41) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL4941280 | 0.82 | TSHR (0.47) | TSHRALDH1A1 | |
| SCHEMBL563000 | 0.82 | TSHR (0.47) | TSHRALDH1A1 | |
| SCHEMBL562999 | 0.82 | TSHR (0.47) | TSHRALDH1A1 | |
| SCHEMBL7342396 | 0.81 | CA1 (0.44) | ALOX15 | |
| SCHEMBL14367745 | 0.81 | CA1 (0.44) | ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1339669-B1 | N-ALKYLATED GABA COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | UCB PHARMA SA (BE) | 2008-06-04 | — | — | EP | claimed |
| EP-0162036-B1 | (S)-ALPHA-ETHYL-2-OXO-1-PYRROLIDINACETAMIDE | U C B, S.A. (BE) | 1989-08-16 | — | — | EP | claimed |
| EP-0165919-B1 | (R)-ALPHA-ETHYL-2-OXO-1-PYRROLIDINACETAMIDE | U C B, S.A. (BE) | 1989-08-09 | — | — | EP | claimed |
| EP-0165919-A1 | (R)-alpha-ethyl-2-oxo-1-pyrrolidinacetamide | U C B, S.A. (BE) | 1985-12-27 | — | — | EP | claimed |
| EP-0162036-A1 | (S)-alpha-ethyl-2-oxo-1-pyrrolidinacetamide | U C B, S.A. (BE) | 1985-11-21 | — | — | EP | claimed |
| EP-3812377-A1 | BRIVARACETAM INTERMEDIATE, PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR BRIVARACETAM | Shanghai Puyi Chemical Co., Ltd. (CN) | 2021-04-28 | — | — | EP | disclosed |
| WO-2019242192-A1 | BRIVARACETAM INTERMEDIATE, PREPARATION METHOD THEREFOR, AND PREPARATION METHOD FOR BRIVARACETAM | 上海朴颐化学科技有限公司 | 2019-12-26 | — | — | WO | disclosed |
| EP-1598337-B1 | METHOD OF OBTAINING AN ANTIEPILEPTIC AGENT | ESTEVE QUIMICA SA (ES) | 2012-05-09 | — | — | EP | disclosed |
| EP-2049476-A1 | PROCESS FOR THE PREPARATION OF LEVETIRACETAM | ZaCh System S.p.A. (IT) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012268-A1 | PROCESS FOR THE PREPARATION OF LEVETIRACETAM | ZACH SYSTEM S.P.A. (IT) | 2008-01-31 | — | — | WO | disclosed |
| US-7291746-B2 | Process for obtaining an antiepileptic agent | ESTEVE QUIMICA, S.A. (ES) | 2007-11-06 | — | — | US | disclosed |
| US-20060142376-A1 | Method for obtaining an antiepileptic agent | ESTEVE QUIMICA, S.A. (ES) | 2006-06-29 | — | — | US | disclosed |
| EP-0162036-B1 | (S)-ALPHA-ETHYL-2-OXO-1-PYRROLIDINACETAMIDE | U C B, S.A. (BE) | 1989-08-16 | — | — | EP | disclosed |
| EP-0165919-B1 | (R)-ALPHA-ETHYL-2-OXO-1-PYRROLIDINACETAMIDE | U C B, S.A. (BE) | 1989-08-09 | — | — | EP | disclosed |
| US-4837223-A | ANTIISCHEMIC AGENTS | UCB SOCIETE ANONYME (BE) | 1989-06-06 | — | — | US | disclosed |
| US-4837224-A | TREATING MEMORY DISORDERS | UCB SOCIETE ANONYME (BE) | 1989-06-06 | — | — | US | disclosed |
| US-4696942-A | Treatment of memory impairment using (R)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide | UCB SOCIETE ANONYME (BE) | 1987-09-29 | — | — | US | disclosed |
| US-4696943-A | ANTIHYPOXIA AND ANTIISCHEMIC AGENTS | U C B SOCIETE ANONYME (BE) | 1987-09-29 | — | — | US | disclosed |
| EP-0165919-A1 | (R)-alpha-ethyl-2-oxo-1-pyrrolidinacetamide | U C B, S.A. (BE) | 1985-12-27 | — | — | EP | disclosed |
| EP-0162036-A1 | (S)-alpha-ethyl-2-oxo-1-pyrrolidinacetamide | U C B, S.A. (BE) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142376-A1 | Method for obtaining an antiepileptic agent | VKORC1, EPM2A, HNMT | AKR1B1 315/4885GPR84 3219/4885PPARG 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.